Inhalation of antibiotics in cystic fibrosis

Aerosol administration of antipseudomonal antibiotics is commonly used in cystic fibrosis. However, its contribution to the improvement of lung function, infection and quality of life is not well-established. All articles published from 1965 until the present time concerning the inhalation of antibiotics in cystic fibrosis were collected by computerized literature search and analysed. Effective aerosol delivery is compromised by nebulizers with limited capacity to produce particles in the respirable range. Twelve studies concerning maintenance treatment were published. Four uncontrolled studies evaluating antibiotic aerosol maintenance treatment in stable patients indicated a beneficial effect in terms of reducing the number of hospital admissions. Eight placebo-controlled studies were found; six of these showed a significant improvement of lung function in the treatment group. Four studies showed a reduction of the number of hospital admissions. In some studies, there was a considerable negative effect of the nebulized placebo solution on the outcome, probably due to the improper choice of its osmolarity. Studies with antibiotic aerosols as adjunct to intravenous therapy in cystic fibrosis patients with an acute exacerbation showed no enhancement of the clinical effects of the intravenous antibiotic by the aerosol; sputum colony counts, however, were lower. Toxicity studies carried out so far have shown no renal or ototoxicity; however, long-term toxicity studies still have to be performed using higher dosages. Introduction or selection of resistant bacteria is relatively rare, but remains a matter of concern. Aerosol maintenance treatment with an appropriate antibiotic in high enough dosage can be recommended for patients with cystic fibrosis chronically infected with P. aeruginosa, and may improve lung function and reduce the number of hospital admissions due to an acute exacerbation.

This article has been cited by other articles:

				M. Mulheran, P. Hyman-Taylor, K. H.-V. Tan, S. Lewis, D. Stableforth, A. Knox, and A. Smyth Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis Patients. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2293 - 2299. [Abstract] [Full Text] [PDF]

				A. Wong-Beringer, M. P. Lambros, P. M. Beringer, and D. L. Johnson Suitability of Caspofungin for Aerosol Delivery: Physicochemical Profiling and Nebulizer Choice Chest, November 1, 2005; 128(5): 3711 - 3716. [Abstract] [Full Text] [PDF]

				P. G. Middleton, T. J. Kidd, and B. Williams Combination aerosol therapy to treat Burkholderia cepacia complex Eur. Respir. J., August 1, 2005; 26(2): 305 - 308. [Abstract] [Full Text] [PDF]

				S P Conway Nebulized antibiotic therapy: the evidence Chronic Respiratory Disease, January 1, 2005; 2(1): 35 - 41. [Abstract] [PDF]

				M E. Drobnic, P. Sune, J B. Montoro, A. Ferrer, and R. Orriols Inhaled Tobramycin in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas aeruginosa Ann. Pharmacother., January 1, 2005; 39(1): 39 - 44. [Abstract] [Full Text] [PDF]

				N M Byrne, P M Keavey, J D Perry, F K Gould, and D A Spencer Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis Arch. Dis. Child., August 1, 2003; 88(8): 715 - 718. [Abstract] [Full Text] [PDF]

				D. E. Geller, M. Rosenfeld, D. A. Waltz, and R. W. Wilmott Efficiency of Pulmonary Administration of Tobramycin Solution for Inhalation in Cystic Fibrosis Using an Improved Drug Delivery System Chest, January 1, 2003; 123(1): 28 - 36. [Abstract] [Full Text] [PDF]

				M.E. Hodson, C.G. Gallagher, and J.R.W. Govan A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Eur. Respir. J., September 1, 2002; 20(3): 658 - 664. [Abstract] [Full Text] [PDF]

				D. E. Geller, W. H. Pitlick, P. A. Nardella, W. G. Tracewell, and B. W. Ramsey Pharmacokinetics and Bioavailability of Aerosolized Tobramycin in Cystic Fibrosis* Chest, July 1, 2002; 122(1): 219 - 226. [Abstract] [Full Text] [PDF]

				R. J. Kuhn Formulation of Aerosolized Therapeutics Chest, September 1, 2001; 120(3_suppl): 94S - 98S. [Abstract] [Full Text] [PDF]

				P-F. Dequin, F. Faurisson, E. Lemarie, F. Delatour, S. Marchand, C. Valat, E. Boissinot, C. de Gialluly, and P. Diot Urinary excretion reflects lung deposition of aminoglycoside aerosols in cystic fibrosis Eur. Respir. J., August 1, 2001; 18(2): 316 - 322. [Abstract] [Full Text] [PDF]

				N. RENÉE CROWTHER LABIRIS, A. M. HOLBROOK, H. CHRYSTYN, S. M. MACLEOD, and M. T. NEWHOUSE Dry Powder versus Intravenous and Nebulized Gentamicin in Cystic Fibrosis and Bronchiectasis . A Pilot Study Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1711 - 1716. [Abstract] [Full Text]

				P. W. Campbell III and L. Saiman Use of Aerosolized Antibiotics in Patients With Cystic Fibrosis Chest, September 1, 1999; 116(3): 775 - 788. [Full Text] [PDF]

				D. Wilson, M. Burniston, E. Moya, A. Parkin, S. Smye, P. Robinson, and J. Littlewood Improvement of nebulised antibiotic delivery in cystic fibrosis Arch. Dis. Child., April 1, 1999; 80(4): 348 - 352. [Abstract] [Full Text]

				E Ring, E Eber, W Erwa, and M S Zach Urinary N-acetyl-beta -D-glucosaminidase activity in patients with cystic fibrosis on long term gentamicin inhalation Arch. Dis. Child., June 1, 1998; 78(6): 540 - 543. [Abstract] [Full Text]